266 related articles for article (PubMed ID: 33402392)
1. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people.
Hopkinson NS; Rossi N; El-Sayed Moustafa J; Laverty AA; Quint JK; Freidin M; Visconti A; Murray B; Modat M; Ourselin S; Small K; Davies R; Wolf J; Spector TD; Steves CJ; Falchi M
Thorax; 2021 Jul; 76(7):714-722. PubMed ID: 33402392
[TBL] [Abstract][Full Text] [Related]
2. Influence of the SARS-CoV-2 Outbreak on the Uptake of a Popular Smoking Cessation App in UK Smokers: Interrupted Time Series Analysis.
Perski O; Herbeć A; Shahab L; Brown J
JMIR Mhealth Uhealth; 2020 Jun; 8(6):e19494. PubMed ID: 32463375
[TBL] [Abstract][Full Text] [Related]
3. App-Based Tracking of Self-Reported COVID-19 Symptoms: Analysis of Questionnaire Data.
Zens M; Brammertz A; Herpich J; Südkamp N; Hinterseer M
J Med Internet Res; 2020 Sep; 22(9):e21956. PubMed ID: 32791493
[TBL] [Abstract][Full Text] [Related]
4. Syndromic Surveillance Insights from a Symptom Assessment App Before and During COVID-19 Measures in Germany and the United Kingdom: Results From Repeated Cross-Sectional Analyses.
Mehl A; Bergey F; Cawley C; Gilsdorf A
JMIR Mhealth Uhealth; 2020 Oct; 8(10):e21364. PubMed ID: 32997640
[TBL] [Abstract][Full Text] [Related]
5. Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers.
Soriano JB; Fernández E; de Astorza Á; Pérez de Llano LA; Fernández-Villar A; Carnicer-Pont D; Alcázar-Navarrete B; García A; Morales A; Lobo M; Maroto M; Ferreras E; Soriano C; Del Rio-Bermudez C; Vega-Piris L; Basagaña X; Muncunill J; Cosio BG; Lumbreras S; Catalina C; Alzaga JM; Gómez Quilón D; Valdivia CA; de Lara C; Ancochea J
JMIR Public Health Surveill; 2020 Sep; 6(3):e21653. PubMed ID: 32845852
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection in the first trimester and the risk of early miscarriage: a UK population-based prospective cohort study of 3041 pregnancies conceived during the pandemic.
Balachandren N; Davies MC; Hall JA; Stephenson JM; David AL; Barrett G; O'Neill HC; Ploubidis GB; Yasmin E; Mavrelos D
Hum Reprod; 2022 May; 37(6):1126-1133. PubMed ID: 35389480
[TBL] [Abstract][Full Text] [Related]
7. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app.
Bowyer RCE; Varsavsky T; Thompson EJ; Sudre CH; Murray BAK; Freidin MB; Yarand D; Ganesh S; Capdevila J; Bakker E; Cardoso MJ; Davies R; Wolf J; Spector TD; Ourselin S; Steves CJ; Menni C
Thorax; 2021 Jul; 76(7):723-725. PubMed ID: 33376145
[TBL] [Abstract][Full Text] [Related]
8. Association of smoking status with outcomes in hospitalised patients with COVID-19.
Adrish M; Chilimuri S; Mantri N; Sun H; Zahid M; Gongati S; Fortuzi K; Jog AP; Purmessur P; Singhal R
BMJ Open Respir Res; 2020 Oct; 7(1):. PubMed ID: 33020114
[TBL] [Abstract][Full Text] [Related]
9. Association Between Smoking and SARS-CoV-2 Infection: Cross-sectional Study of the EPICOVID19 Internet-Based Survey.
Prinelli F; Bianchi F; Drago G; Ruggieri S; Sojic A; Jesuthasan N; Molinaro S; Bastiani L; Maggi S; Noale M; Galli M; Giacomelli A; Antonelli Incalzi R; Adorni F; Cibella F;
JMIR Public Health Surveill; 2021 Apr; 7(4):e27091. PubMed ID: 33668011
[TBL] [Abstract][Full Text] [Related]
10. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).
Simons D; Shahab L; Brown J; Perski O
Addiction; 2021 Jun; 116(6):1319-1368. PubMed ID: 33007104
[TBL] [Abstract][Full Text] [Related]
11. Early detection of COVID-19 in the UK using self-reported symptoms: a large-scale, prospective, epidemiological surveillance study.
Canas LS; Sudre CH; Capdevila Pujol J; Polidori L; Murray B; Molteni E; Graham MS; Klaser K; Antonelli M; Berry S; Davies R; Nguyen LH; Drew DA; Wolf J; Chan AT; Spector T; Steves CJ; Ourselin S; Modat M
Lancet Digit Health; 2021 Sep; 3(9):e587-e598. PubMed ID: 34334333
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.
de Lusignan S; Dorward J; Correa A; Jones N; Akinyemi O; Amirthalingam G; Andrews N; Byford R; Dabrera G; Elliot A; Ellis J; Ferreira F; Lopez Bernal J; Okusi C; Ramsay M; Sherlock J; Smith G; Williams J; Howsam G; Zambon M; Joy M; Hobbs FDR
Lancet Infect Dis; 2020 Sep; 20(9):1034-1042. PubMed ID: 32422204
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app.
Visconti A; Murray B; Rossi N; Wolf J; Ourselin S; Spector TD; Freeman EE; Bataille V; Falchi M
Br J Dermatol; 2022 Dec; 187(6):900-908. PubMed ID: 35869671
[TBL] [Abstract][Full Text] [Related]
14. Smoking and risk of COVID-19 hospitalization.
Puebla Neira D; Watts A; Seashore J; Polychronopoulou E; Kuo YF; Sharma G
Respir Med; 2021 Jun; 182():106414. PubMed ID: 33915414
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
17. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
